News
Novel coronavirus pneumonia ( coronavirus disease 2019,COVID-19) The epidemic continues to be prevalent around the world and has become an important public health problem, seriously threatening human health. At present, the treatment of the new crown virus is still based on symptomatic treatment, there is no effective antiviral therapy, vaccination is one of the most effective measures to prevent and control the new crown pneumonia, for this reason, the successful development and marketing of the new crown vaccine has great social and commercial value.
At present, China's new crown vaccine research and development in the world's leading state, as2021 year3 in January, a total of five vaccines were approved for emergency marketing (three inactivated vaccines, one adenovirus vector vaccine, and one recombinant protein vaccine), and when vaccines are produced using highly pathogenic microorganisms or specific strains of bacteria (viruses), the relevant production workshops are workshops with high biosafety risks,
A high level of biosafety protection is required.Sinopharm Engineering has accumulated rich experience in the construction of biopharmaceutical engineering. In recent years, it has undertaken a number of domestic high-level biosafety facilities and biopharmaceutical projects with significant impact, such as the foot-and-mouth disease vaccine production base of Yangling Jinhai Biotechnology Co., Ltd. BSL-3( P31) Plant, ABSL-3( b2 class) ( P3) Animal Experiment Center Construction Project, Wuhan University SPF ABSL-3
Animal Laboratory Project, School of Medicine, Shihezi University BSL-3/ABLS-3( P3) laboratory Animal Center Project, Xinjiang Animal Disease Prevention and Control Technology Research Center BSL-3 with ABSL-3 laboratory Engineering, Qingdao Yibang Bioengineering Company BSL-3 plant, ABSL-3( b2 class) animal laboratories, etc.2020
At the beginning of the outbreak of the new crown epidemic in, the Wuhan Division of the National Pharmaceutical Engineering transferred relevant experts to carry out research in advance on the technical problems of engineering construction that may be involved in the prevention and control of the epidemic, and prepared the report "Technical Standards for the Construction of New Crown Vaccine Production Workshop and Recommendations for the Selection of Related Facilities" to provide technical support for the formulation of relevant laws and regulations by the State. And for the new crown vaccine different process routes, combined with our previous project experience and design standard research results, the development of a number of system solutions, in order to speed up the new crown vaccine production and marketing escort. The unitAt present, Sinoparmaceutics Engineering is using its own system solutions for the production of new crown vaccines such as Jiangsu Ruike Biotechnology Co. The purpose is to provide design technical services. The above projects will largely alleviate the shortage of new crown vaccines in China, and will also provide more vaccine products made in China for the international market. It is expected that China's vaccines will build a solid barrier for national immunization and contribute to the ultimate victory over the epidemic and ensure the safety and health of the people.
(Headquarters Wuhan Division)
Company News
